微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 86.09% | 4.81% | 3.54% | 7/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 83.15% | 2.22% | 0.06% | 17/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 83.1% | 1.71% | -1.23% | 16/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 84.14% | 1.73% | 2.44% | 14/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 82.14% | -0.14% | 0.97% | 17/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 81.35% | 8.02% | -0.44% | 20/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 81.71% | 8.41% | -1.21% | 18/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 82.71% | 10.14% | 0.56% | 18/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 82.25% | 12.06% | 9.22% | 19/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 75.3% | -7.2% | -0.08% | 33/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 75.37% | -8.02% | 0.36% | 33/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 75.1% | -8.32% | 2.31% | 34/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 73.4% | -9.51% | -9.56% | 35/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 81.15% | 7.19% | -0.97% | 24/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 81.94% | 9.28% | 0.04% | 19/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 81.91% | 9.64% | 0.99% | 20/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 81.11% | 3.28% | 7.13% | 17/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 75.71% | -5.07% | 0.97% | 27/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 74.98% | -7.99% | 0.37% | 26/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 74.7% | -9% | -4.88% | 26/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 78.53% | -3.77% | -1.53% | 21/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 79.76% | -7.5% | -2.13% | 19/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 81.49% | -5.49% | -0.73% | 11/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 82.09% | -4.55% | 0.59% | 15/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 81.61% | -3.66% | -5.36% | 12/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 86.23% | 9.07% | 0% | 12/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 86.23% | 10.79% | 0.26% | 7/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 86% | 14.03% | 1.53% | 9/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 84.71% | 15.18% | 7.15% | 10/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 79.06% | 17.08% | 1.58% | 18/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 77.83% | 2% | 3.2% | 9/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 75.42% | 15.66% | 2.54% | 11/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 73.55% | 2% | 8.92% | 12/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 67.52% | 9.81% | 3.55% | 21/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 65.21% | 2% | 6.04% | 20/159 | 46.2% | 贝达药业 | 95.89% | 行业排名> |
| 2015-12-31 | 61.49% | 2.73% | 2.73% | 26/159 | 46.24% | 微芯生物 | 97.46% | 行业排名> |